ARQL - ArQule, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.36
-0.22 (-2.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.58
Open9.58
Bid9.65 x 800
Ask9.70 x 800
Day's Range9.17 - 9.90
52 Week Range2.23 - 9.92
Volume5,833,577
Avg. Volume2,401,156
Market Cap1.023B
Beta (3Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.44
Trade prices are not sourced from all markets
  • Business Wire9 hours ago

    ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019

    ArQule, Inc. (ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Benzinga17 hours ago

    The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...

  • Benzinga2 days ago

    ArQule Hits 12-Year High Following Favorable Midstage Study Results

    Close on the heels of a 30% rally Friday on the back of positive results from an early stage study of its leukemia drug candidate, ArQule announced preliminary results from a Phase 1/2 study of its pan-AKT inhibitor miransertib, or ARQ 092, in patients with PIK3CA-related Overgrowth Spectrum, or PROS, and Proteus syndrome, or PS. The data was presented at the European Society of Human Genetics Conference in Gothenburg, Sweden. The recommended initial dose for the registrational study was defined as a 15mg/square meter once-daily dose, with a subsequent maximum dose increase to 25 mg/square meter.

  • 2 Rallying Pharma Stocks Roping In Option Bulls
    Schaeffer's Investment Research2 days ago

    2 Rallying Pharma Stocks Roping In Option Bulls

    Short sellers could be shaking in their boots

  • Here's Why ArQule Is Soaring Again Today
    Motley Fool2 days ago

    Here's Why ArQule Is Soaring Again Today

    A new day, a new batch of promising interim data from an early-stage clinical study.

  • Company News For Jun 17, 2019
    Zacks2 days ago

    Company News For Jun 17, 2019

    Companies In The News Are: FB,BXG,ARQL,KURA

  • Business Wire2 days ago

    ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference

    ArQule, Inc. (ARQL) today announced preliminary results from the company’s phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference in Gothenburg, Sweden.

  • Benzinga4 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

    For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...

  • ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results
    InvestorPlace5 days ago

    ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results

    ArQule (NASDAQ:ARQL) began the day and ended the week with a bang as the company's latest blood cancer treatment has shown early signs of promise in helping patients with tumors heal.The Woburn, Mass.-based pharmaceutical business announced its preliminary data from a Phase 1 trial in regards to its investigational cancer drug ARQ 531. The company's early-stage trial is still ongoing, and it examined the effects of several different doses of the drug in 34 patients suffering from advanced chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), Richter's Transformation, Waldenstrom macroglobulinemia as well as other B-cell Non-Hodgkin lymphomas.ArQule's Phase 1 trials are designed to establish a recommended dose of a new drug for study for the Phase 2 trials. Researchers from the study looking at ARQ 531 said patients were fine at dosages of up to 65 milligrams once a day.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe drug displayed promising anti-tumor activity in some patients, according to the company. "We are now focused on finalizing the recommended Phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy," said ArQule Chief Medical Officer Brian Schwartz in a statement.ARQL stock is soaring a whopping 32.6% following the company's news on Friday. This helped push the company's per share price to a 12-year high of $8.34. More From InvestorPlace * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Stocks to Buy for the Coming Recession * 7 High-Quality Cheap Stocks to Buy With $10 Compare Brokers The post ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results appeared first on InvestorPlace.

  • Benzinga5 days ago

    A Look At Benzinga Pro's Most-Searched Tickers For June 14

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ArQule, Inc. (NASDAQ: ARQL ) shares were up ...

  • Here's Why ArQule Shares Rose as Much as 44.7% Today
    Motley Fool5 days ago

    Here's Why ArQule Shares Rose as Much as 44.7% Today

    The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.

  • TheStreet.com5 days ago

    ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results

    shares are up more than 35% Friday after the company announced positive phase 1 results from the trial of its orally bioavailable, potent and reversible dual inhibitor for patients with relapsed or refractory hematologic malignancies. "The profile of ARQ 531 continues to strengthen, and we are delighted to be able to demonstrate such compelling clinical activity at a well-tolerated dose in patients who have already exhausted available therapies," commented Dr. Brian Schwartz, Chief Medical Officer of ArQule. The phase 1 study is an open label, single arm dose escalation study with eight levels of dosage once a day in patients with relapsed or refractory chronic lymophcytic leukemia.

  • Benzinga5 days ago

    Why Small-Cap Biotech ArQule Is Rallying

    Shares of ArQule, Inc. (NASDAQ: ARQL ) are galloping toward a multiyear high in the wake of the presentation of a clinical trial readout. What Happened The small-cap biotech   announced preliminary results ...

  • Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study
    Motley Fool5 days ago

    Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study

    Stocks were poised to ease lower on Friday morning.

  • MarketWatch5 days ago

    ArQule stock rockets 49% toward 12-year high after biotech announces Phase 1 trial results

    Shares of biotech ArQule Inc. shot up 49% toward a 12-year high in premarket trade Friday after the company announced preliminary data from a Phase 1 trial of its investigational cancer drug ARQ 531. The early-stage trial, which is still ongoing, looks at several different doses of the drug in 34 patients with advanced chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), Richter's Transformation, Waldenström macroglobulinemia or other B-cell Non-Hodgkin lymphomas. The goal of such Phase 1 trials is to establish a recommended dose of a new drug for study in Phase 2 trials. Researchers looking at ARQ 531 said patients were fine at dosages up to 65 milligrams once a day. The drug demonstrated promising anti-tumor activity in some patients, according to the company. "We are now focused on finalizing the recommended Phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy," said ArQule Chief Medical Officer Brian Schwartz in a statement. Shares of ArQule have gained 127% so far this year, while the S&P 500 has gained 15.3%.

  • Benzinga5 days ago

    The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...

  • Business Wire5 days ago

    ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting

    ArQule, Inc. (ARQL) today announced preliminary results from the Company’s phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association (EHA) Annual Meeting in Amsterdam, the Netherlands.

  • Imagine Holding ArQule (NASDAQ:ARQL) Shares While The Price Zoomed 346% Higher
    Simply Wall St.9 days ago

    Imagine Holding ArQule (NASDAQ:ARQL) Shares While The Price Zoomed 346% Higher

    For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...

  • Business Wire9 days ago

    ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

    Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome

  • Business Wire12 days ago

    ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)

    Presentation highlights phase 1 dose escalation study in patients with relapsed or refractory B-cell lymphoid malignancies

  • Business Wire20 days ago

    ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019 Healthcare Conference on June 6, 2019 at 11:30 a.m. ET at the Grand Hyatt in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Harry Boxer’s three stocks to watch include Roku
    MarketWatch28 days ago

    Harry Boxer’s three stocks to watch include Roku

    Three stocks that had been digesting recent gains now appear to be on the rise again. ArQule Inc. (ARQL) gained 42 cents to $7.17 on 2.6 million shares traded Tuesday. The move came on no news from the biopharmaceutical company.

  • Benzinga28 days ago

    The Tech Trader's 3 Stocks On The Move

    Three stocks that had been digesting recent gains now appear to be on the rise again. ArQule, Inc. (NASDAQ: ARQL ) gained 42 cents to $7.17 on 2.6 million shares Tuesday. The move, on more than 1/2 times ...

  • Business Wirelast month

    ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

    ArQule, Inc. (ARQL) today announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m. PT at the Beverly Hilton in Beverly Hills, CA. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

  • Business Wirelast month

    ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019

    ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at the InterContinental New York Barclay in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.